Preclinical assessment and randomized Phase I study of CT-P63, a broadly neutralizing antibody targeting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

Preclinical assessment and randomized Phase I study of CT-P63, a broadly neutralizing antibody targeting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

The pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has resulted in significant morbidity and mortality worldwide. Despite a successful vaccination programme, the emergence of mutated variants that can escape current levels of immunity mean infections continue. Herein...

Full description

Bibliographic Details
Main Authors: Ji-Min Seo, Bobin Kang, Rina Song, Hanmi Noh, Cheolmin Kim, Jong-In Kim, Minsoo Kim, Dong-Kyun Ryu, Min-Ho Lee, Jeong-Sun Yang, Kyung-Chang Kim, Joo-Yeon Lee, Hansaem Lee, Hye-Min Woo, Jun-Won Kim, Jung-Ah Choi, Manki Song, Monika Tomaszewska-Kiecana, Anna Wołowik, Agnieszka Kulesza, Sunghyun Kim, Keumyoung Ahn, Nahyun Jung, Soo-Young Lee
Format: Article
Language:English
Published: Taylor & Francis Group 2022-12-01
Series:Emerging Microbes and Infections
Subjects:
COVID-19
SARS-CoV-2 variants of concern
neutralizing antibody
monoclonal antibody
CT-P63
Online Access:https://www.tandfonline.com/doi/10.1080/22221751.2022.2117094

Internet

https://www.tandfonline.com/doi/10.1080/22221751.2022.2117094

Similar Items